Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines

Breast

Volumn 14, Issue 4, 2005, Pages 304-309

  Ahn, Jin Hee ^a   Kim, Sung Bae ^a   Sohn, Hee Jung ^a   Lee, Jung Shin ^a   Kang, Yoon Koo ^a   Kim, Woo Kun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Anthracycline; Breast neoplasms; Cisplatin; Docetaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FOLLOW UP; HEART PALPITATION; HUMAN; METASTASIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THORAX PAIN; THROMBOCYTOPENIA;

EID: 23444434071     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.02.006     Document Type: Article

References (31)

1. R.T. Greenlee M.B. Hill-Harmon T. Murray et al. Cancer statistics, 2001 CA Cancer J Clin 51 2001 15-36
2. C.T. Chung R.W. Carlson Goals and objectives in the management of metastatic breast cancer Oncologist 8 2003 514-520
3. D.F. Hayer I.C. Henderson C.L. Sharpiro Treatment of metastatic breast cancer: Present and future prospects Semin Oncol 22 Suppl 5 1995 5-21
4. J.M. Nabholtz A. Riva Taxane/anthracycline combinations: Setting a new standard in breast cancer? Oncologist 6 Suppl 3 2001 5-12
5. J.M. Nabholtz C. Falkson D. Campos et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial J Clin Oncol 15 2003 968-975
6. J.E. Cortes R. Pazdur Docetaxel J Clin Oncol 13 1995 2643-2655
7. V. Valero Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy Semin Oncol 24/4 Suppl 13 1997 11-18
8. P.M. Ravdin Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer Semin Oncol 24/4 Suppl 10 1997 18-21
9. S. Chan K. Friedrichs D. Noel et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 1999 2341-2354
10. J. Nabholtz H. Senn W. Bezwoda et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy J Clin Oncol 17 1999 1413-1424
11. V. Valero S.E. Jones D.D. Von Hoff et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 1998 3362-3368
12. K. Kolaric A. Roth Phase II clinical trial of cisdichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer Cancer Chem Pharmacol 11 1983 108-112
13. G.W. Sledge P.J. Loehrer B.J. Roth et al. Cisplatin as first-line therapy for metastatic breast cancer J Clin Oncol 6 1988 1811-1814
14. H.Y. Yap P. Salem G.N. Hortobagyi et al. Phase II study of cisdichlorodiammineplatinum in advanced breast cancer Cancer Treat Rep 62 1978 405-408
15. A.A. Forastiere T. Hakes J.T. Witters et al. Cisplatin in the treatment of metastatic breast cancer Am J Clin Oncol 5 1982 243-247
16. J.P. Crown The platinum agents: A role in breast cancer treatment? Semin Oncol 28 Suppl 3 2001 28-37
17. M.P. Decatris S. Sundar K.J. O'Byrne Platinum-based chemotherapy in metastatic breast cancer: Current status Cancer Treat Rev 4 2004 53-81
18. J. Hurley P. Doliny C. Gomez et al. High complete pathologic response rate of locally advanced breast cancers (LABC) to neoadjuvant docetaxel and cisplatin chemotherapy Proc Am Soc Clin Oncol 19 2000 494a
19. C. Gainford M. O'Leary T. El-Fiki et al. Phase I trial of docetaxel (T) and cisplatin (P) as first line chemotherapy for metastatic breast cancer Proc Am Soc Clin Oncol 19 2000 439a
20. V. Pescia H.R. Bordenave S. Foglia et al. Taxotere (T) and cisplatin (P) in anthracycline-pretreated advanced breast cancer (ABC): Preliminary results Proc Am Soc Clin Oncol 19 2000 117a
21. M. Spielmann A. Llombart L. Zelek et al. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer Ann Oncol 10 1999 1457-1460
22. E.C. Antoine J.B. Meric D. Coeffic et al. Anthracycline-primary resistant breast cancer (APRBC): Confirmatory results of the high level of activity of the docetaxel (D)-cisplatin (C) regimen Proc Am Soc Clin Oncol 18 1999 491a
23. M. Vassilomanoakis G. Koumakis S. Droufakou et al. First-line chemotherapy of metastatic breast cancer with docetaxel/cisplatin and lenograstim support: Preliminary results Proc Am Soc Clin Oncol 21 2002 1972a
24. J. O'Shaughnessy D. Miles S. Vukelja et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results J Clin Oncol 20 2002 2812-2823
25. G.N. Hortobagyi Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer Clin Breast Cancer 3 Suppl 1 2002 S34-S38
26. J. O'Shaughnessy S. Nag G. Calderillo-Ruiz et al. Gemzar plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracylcine pretreated metastatic breast cancer (MBC): Interim results of a global phase III study Proc Am Soc Clin Oncol 22 2003 25a
27. J.-H. Ahn S.-B. Kim T.-W. Kim et al. Capecitabine and vinorelbine in patients previously treated with anthracycline and taxane J Kor Med Science 19 2004 547-553
28. M.D. Pegram A. Lopez G. Konecny et al. Trastuzumab and chemotherapeutics: Drug interactions and synergies Semin Oncol 27 2000 21-25
29. D. Slamon M.D. Pegram Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials Semin Oncol 28 1 Suppl 3 2001 13-19
30. D.J. Slamon B. Leyland-Jones S. Shak et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783-792
31. M.D. Pegram T. Pienkowski D.W. Northfelt et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER-2-positive advanced breast cancer Natl Cancer Inst 19 2004 759-769